Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coronavirus vaccine + influenza vaccine
- Development stage
- Preclinical
- Lead developer
- SwiftPharma
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Coronavirus vaccine + influenza vaccine is a preclinical combination vaccine candidate being developed by SwiftPharma. The vaccine utilizes SwiftPharma's proprietary plant-based production platform to generate Highly Mannosylated Virus-Like Particles (VLPs). This technology is designed to enhance the immunogenicity of the vaccine by mimicking the structural characteristics of the target viruses—specifically coronavirus (SARS-CoV-2) and influenza—to elicit a broad and protective immune response. By producing these VLPs in plants, the platform aims to provide a scalable and efficient method for manufacturing complex therapeutic proteins that can effectively prime the immune system against multiple respiratory pathogens simultaneously.
- Other names
- Coronavirus/Influenza combo vaccineHighly Mannosylated VLP vaccineSwiftPharma Coronavirus/Influenza vaccine
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on coronavirus vaccine + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coronavirus vaccine + influenza vaccine.